vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and SPIRE INC (SR). Click either name above to swap in a different company.

SPIRE INC is the larger business by last-quarter revenue ($762.2M vs $722.5M, roughly 1.1× Amneal Pharmaceuticals, Inc.). SPIRE INC runs the higher net margin — 12.5% vs 10.8%, a 1.7% gap on every dollar of revenue. On growth, SPIRE INC posted the faster year-over-year revenue change (13.9% vs 3.9%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -17.8%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Spire Inc. is a regional public utility holding company based in St. Louis, Missouri, providing natural gas service through its regulated core utility operations while engaging in non-regulated activities that provide business opportunities. Its primary subsidiary Laclede Gas Company is the largest natural gas distribution utility in Missouri, serving approximately 631,000 residential, commercial and industrial customers in the City of St. Louis and ten counties in eastern Missouri. Its corpo...

AMRX vs SR — Head-to-Head

Bigger by revenue
SR
SR
1.1× larger
SR
$762.2M
$722.5M
AMRX
Growing faster (revenue YoY)
SR
SR
+10.0% gap
SR
13.9%
3.9%
AMRX
Higher net margin
SR
SR
1.7% more per $
SR
12.5%
10.8%
AMRX
Faster 2-yr revenue CAGR
AMRX
AMRX
Annualised
AMRX
1.5%
-17.8%
SR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMRX
AMRX
SR
SR
Revenue
$722.5M
$762.2M
Net Profit
$78.0M
$95.0M
Gross Margin
44.3%
55.1%
Operating Margin
19.6%
22.8%
Net Margin
10.8%
12.5%
Revenue YoY
3.9%
13.9%
Net Profit YoY
410.5%
16.9%
EPS (diluted)
$0.19
$1.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
SR
SR
Q1 26
$722.5M
Q4 25
$814.3M
$762.2M
Q3 25
$784.5M
$334.1M
Q2 25
$724.5M
$421.9M
Q1 25
$695.4M
$1.1B
Q4 24
$730.5M
$669.1M
Q3 24
$702.5M
$293.8M
Q2 24
$701.8M
$414.1M
Net Profit
AMRX
AMRX
SR
SR
Q1 26
$78.0M
Q4 25
$35.1M
$95.0M
Q3 25
$2.4M
$-39.8M
Q2 25
$22.4M
$20.9M
Q1 25
$12.2M
$209.3M
Q4 24
$-31.1M
$81.3M
Q3 24
$-156.0K
$-25.9M
Q2 24
$6.0M
$-12.6M
Gross Margin
AMRX
AMRX
SR
SR
Q1 26
44.3%
Q4 25
36.5%
55.1%
Q3 25
34.9%
Q2 25
39.5%
Q1 25
36.8%
Q4 24
36.0%
55.6%
Q3 24
38.4%
Q2 24
35.6%
Operating Margin
AMRX
AMRX
SR
SR
Q1 26
19.6%
Q4 25
13.8%
22.8%
Q3 25
9.0%
-0.1%
Q2 25
15.4%
16.4%
Q1 25
14.4%
29.1%
Q4 24
10.4%
22.2%
Q3 24
12.6%
6.7%
Q2 24
13.6%
7.4%
Net Margin
AMRX
AMRX
SR
SR
Q1 26
10.8%
Q4 25
4.3%
12.5%
Q3 25
0.3%
-11.9%
Q2 25
3.1%
5.0%
Q1 25
1.8%
19.9%
Q4 24
-4.3%
12.2%
Q3 24
-0.0%
-8.8%
Q2 24
0.9%
-3.0%
EPS (diluted)
AMRX
AMRX
SR
SR
Q1 26
$0.19
Q4 25
$0.10
$1.54
Q3 25
$0.01
$-0.77
Q2 25
$0.07
$0.29
Q1 25
$0.04
$3.51
Q4 24
$-0.10
$1.34
Q3 24
$0.00
$-0.63
Q2 24
$0.02
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
SR
SR
Cash + ST InvestmentsLiquidity on hand
$197.7M
$4.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.4B
Total Assets
$3.5B
$11.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
SR
SR
Q1 26
$197.7M
Q4 25
$282.0M
$4.1M
Q3 25
$201.2M
$5.7M
Q2 25
$71.5M
$13.1M
Q1 25
$59.2M
$15.2M
Q4 24
$110.6M
$11.5M
Q3 24
$74.0M
$4.5M
Q2 24
$43.8M
$7.4M
Total Debt
AMRX
AMRX
SR
SR
Q1 26
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
AMRX
AMRX
SR
SR
Q1 26
Q4 25
$-70.8M
$3.4B
Q3 25
$-109.5M
$3.4B
Q2 25
$-112.1M
$3.5B
Q1 25
$-131.7M
$3.5B
Q4 24
$-109.3M
$3.3B
Q3 24
$-93.4M
$3.2B
Q2 24
$-57.5M
$3.3B
Total Assets
AMRX
AMRX
SR
SR
Q1 26
$3.5B
Q4 25
$3.7B
$11.9B
Q3 25
$3.6B
$11.6B
Q2 25
$3.4B
$11.4B
Q1 25
$3.4B
$11.3B
Q4 24
$3.5B
$11.3B
Q3 24
$3.5B
$10.9B
Q2 24
$3.5B
$10.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
SR
SR
Operating Cash FlowLast quarter
$81.0M
Free Cash FlowOCF − Capex
$-121.8M
FCF MarginFCF / Revenue
-16.0%
Capex IntensityCapex / Revenue
26.6%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$-286.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
SR
SR
Q1 26
Q4 25
$130.3M
$81.0M
Q3 25
$118.5M
$-4.9M
Q2 25
$83.8M
$129.1M
Q1 25
$7.4M
$372.7M
Q4 24
$118.1M
$81.1M
Q3 24
$141.8M
$82.9M
Q2 24
$39.7M
$270.1M
Free Cash Flow
AMRX
AMRX
SR
SR
Q1 26
Q4 25
$108.5M
$-121.8M
Q3 25
$106.2M
$-227.6M
Q2 25
$61.0M
$-91.4M
Q1 25
$-5.8M
$154.1M
Q4 24
$102.9M
$-179.5M
Q3 24
$124.8M
$-146.9M
Q2 24
$29.0M
$47.9M
FCF Margin
AMRX
AMRX
SR
SR
Q1 26
Q4 25
13.3%
-16.0%
Q3 25
13.5%
-68.1%
Q2 25
8.4%
-21.7%
Q1 25
-0.8%
14.7%
Q4 24
14.1%
-26.8%
Q3 24
17.8%
-50.0%
Q2 24
4.1%
11.6%
Capex Intensity
AMRX
AMRX
SR
SR
Q1 26
Q4 25
2.7%
26.6%
Q3 25
1.6%
66.7%
Q2 25
3.2%
52.3%
Q1 25
1.9%
20.8%
Q4 24
2.1%
38.9%
Q3 24
2.4%
78.2%
Q2 24
1.5%
53.7%
Cash Conversion
AMRX
AMRX
SR
SR
Q1 26
Q4 25
3.72×
0.85×
Q3 25
50.00×
Q2 25
3.74×
6.18×
Q1 25
0.61×
1.78×
Q4 24
1.00×
Q3 24
Q2 24
6.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRX
AMRX

Segment breakdown not available.

SR
SR

Residential$474.9M62%
Commercial And Industrial$148.4M19%
Gas Marketing$41.1M5%
Midstream$39.0M5%
Transportation$37.1M5%
Offsystem And Other Inventive$19.7M3%
Other Customer Revenue$4.6M1%

Related Comparisons